Alibaba Health Information Technology (FRA:TWYA) Research & Development: €97 Mil (TTM As of Mar. 2026)


FRA:TWYA Alibaba Health Information Technology Ltd FRA:TWYA
83 GF Score
Price €5.90
GF Value €9.99
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Alibaba Health Information Technology Research & Development?

Alibaba Health Information Technology FRA:TWYA -3.28% 83 Research & Development is €97 Mil as of Mar. 2026. GuruFocus rates FRA:TWYA with a GF Score™ of 83/100 and a GF Value™ of €9.99 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Alibaba Health Information Technology's Research & Development for the six months ended in Mar. 2026 was €60 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €97 Mil.

Alibaba Health Information Technology  (FRA:TWYA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Alibaba Health Information Technology Research & Development Related Terms

Alibaba Health Information Technology Research & Development Historical Data

* Premium members only.

The historical data trend for Alibaba Health Information Technology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alibaba Health Information Technology Research & Development Chart

Alibaba Health Information Technology Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 104.31 91.87 90.11 91.88 98.94

Alibaba Health Information Technology Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.32 40.65 51.15 37.45 59.65
FRA:TWYA
83GF Score
Alibaba Health Information Technology Ltd FRA:TWYA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alibaba Health Information Technology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €97 Mil mean?
Alibaba Health Information Technology (FRA:TWYA) has a Research & Development of €97 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Alibaba Health Information Technology and its competitors.
Is Alibaba Health Information Technology's Research & Development too high?
Alibaba Health Information Technology's current Research & Development is €97 Mil. Overall, Alibaba Health Information Technology has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alibaba Health Information Technology's Research & Development compare to competitors?
Alibaba Health Information Technology's Research & Development of €97 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Alibaba Health Information Technology and its competitors. Alibaba Health Information Technology's current Research & Development is €97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alibaba Health Information Technology stock overvalued right now?
Based on GuruFocus' analysis, Alibaba Health Information Technology (FRA:TWYA) is currently considered Significantly Undervalued. The stock's GF Value™ is €9.99, compared to a current price of €5.90 — trading 40.9% below its estimated fair value. The current Research & Development is €97 Mil. Alibaba Health Information Technology's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Alibaba Health Information Technology (FRA:TWYA), the current Research & Development is €97 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alibaba Health Information Technology (FRA:TWYA) Overvalued in 2026?

Based on GuruFocus' analysis, Alibaba Health Information Technology stock appears to be undervalued. The current stock price of €5.90 is trading 40.9% below its estimated GF Value™ of €9.99. GuruFocus considers Alibaba Health Information Technology to be Significantly Undervalued.

Key valuation signals for FRA:TWYA:

  • Research & Development: €97 Mil
  • GF Value™: €9.99 vs. price of €5.90 (40.9% below fair value)
  • GF Score™: 83/100 with 2 warning signs

No single metric tells the full story. See the FRA:TWYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alibaba Health Information Technology Business Description

Address Wangjing East Park, 30th Floor, Greenland Center, Building 9, Zone 4, Chaoyang District, Beijing, CHN
Alibaba Health is of one of China's leading e-commerce platform specializing in healthcare-related products, including prescription drugs, OTC drugs, traditional Chinese medicine, health foods, and so on. The company operates both a third-party B2C service, or 3P, and its own direct-to-consumer business, or 1P, with its own inventory, which can both be accessed by Alibaba's Tmall app and Alipay. The company also provides online consultation services in a separate app although its e-commerce businesses remain its core competency in the long-term. E-commerce accounted for 93% of revenue in fiscal year 2022. We estimate that AliHealth holds about 45% of market share in the industry in terms of GMV. AliHealth is 63.74% owned by its parent company, Alibaba Group.
83GF Score

Get the complete analysis for FRA:TWYA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.90
Price
€9.99
GF Value